ATE152169T1 - Modifizierte hepatozyten und deren anwendung - Google Patents

Modifizierte hepatozyten und deren anwendung

Info

Publication number
ATE152169T1
ATE152169T1 AT89902467T AT89902467T ATE152169T1 AT E152169 T1 ATE152169 T1 AT E152169T1 AT 89902467 T AT89902467 T AT 89902467T AT 89902467 T AT89902467 T AT 89902467T AT E152169 T1 ATE152169 T1 AT E152169T1
Authority
AT
Austria
Prior art keywords
application
hepatocytes
interest
genetic material
modified hepatocytes
Prior art date
Application number
AT89902467T
Other languages
English (en)
Inventor
James M Howard Hughes M Wilson
Richard C Mulligan
Original Assignee
Whitehead Biomedical Inst
Hughes Howard Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Hughes Howard Med Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE152169T1 publication Critical patent/ATE152169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
AT89902467T 1988-02-05 1989-02-02 Modifizierte hepatozyten und deren anwendung ATE152169T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15274988A 1988-02-05 1988-02-05

Publications (1)

Publication Number Publication Date
ATE152169T1 true ATE152169T1 (de) 1997-05-15

Family

ID=22544267

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89902467T ATE152169T1 (de) 1988-02-05 1989-02-02 Modifizierte hepatozyten und deren anwendung

Country Status (7)

Country Link
US (3) US5521076A (de)
EP (2) EP0732397A3 (de)
JP (1) JP2917998B2 (de)
AT (1) ATE152169T1 (de)
CA (1) CA1341319C (de)
DE (1) DE68927996T2 (de)
WO (1) WO1989007136A2 (de)

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US6001350A (en) * 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5580776A (en) * 1988-02-05 1996-12-03 Howard Hughes Medical Institute Modified hepatocytes and uses therefor
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
EP1001032A3 (de) * 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2092323A1 (en) * 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
WO1992007573A1 (en) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Genetic modification of endothelial cells
CA2076848A1 (en) * 1990-12-26 1992-06-27 Richard C. Mulligan Modified hepatocytes and uses therefor
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
WO1994015459A1 (en) * 1993-01-05 1994-07-21 The General Hospital Corporation Method for isolation and transplantation of specialized hepatocytes
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
CA2188675A1 (en) * 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
WO1996011268A1 (en) * 1994-10-06 1996-04-18 Warner-Lambert Company Method of using a scavenger receptor in the treatment of atherosclerosis
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
CA2229287A1 (en) * 1995-08-14 1997-02-27 Cornell Research Foundation, Inc. Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US5869243A (en) * 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US5888982A (en) * 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US20040072243A1 (en) * 1996-10-11 2004-04-15 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors
WO1999033971A1 (en) 1997-12-31 1999-07-08 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6808921B1 (en) * 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6080576A (en) * 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU767066B2 (en) 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
IL145055A0 (en) 1999-03-12 2002-06-30 Gpc Biotech Inc Methods and reagents for identifying synthetic genetic elements
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
US6436302B1 (en) 1999-08-23 2002-08-20 Applied Materials, Inc. Post CU CMP polishing for reduced defects
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
JP2003518942A (ja) 1999-12-30 2003-06-17 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 肝細胞成長、形質細胞分化、又はｔ細胞サブセットの活性を、ｘｂｐ−１活性の変調により変調することに関する方法及び組成物
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2419159A1 (en) 2000-08-11 2002-02-21 Agilix Corporation Ultra-sensitive detection systems
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
AU2002252370A1 (en) * 2001-03-12 2002-09-24 Irm, Llc. Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
WO2002072783A2 (en) * 2001-03-12 2002-09-19 Irm, Llc Identification of cellular targets for biologically active molecules
WO2002094871A1 (en) 2001-05-24 2002-11-28 Human Dna Technology Inc Novel keratinocyte growth factor-2 analogue in hair follicle
CA2453183C (en) 2001-07-12 2016-05-10 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
ATE555798T1 (de) 2001-08-09 2012-05-15 Giuseppe Intini Gewebeimplantate und verfahren zur ihrer herstellung und verwendung
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
AU2002343475A1 (en) 2001-10-03 2003-04-14 Selective Genetics, Inc. Traversal of nucleic acid molecules through a fluid space and expression in repair cells
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
AU2003265228A1 (en) * 2002-03-12 2003-12-22 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
AU2003245239A1 (en) 2002-03-25 2003-11-03 Uab Research Foundation FC receptor homolog, reagents, and uses thereof
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2006500030A (ja) 2002-09-20 2006-01-05 イェール ユニバーシティ リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
US8007804B2 (en) 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
EP2258724A1 (de) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
EP1594433B8 (de) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Sensibilisator für krebstherapie
DK1624936T3 (da) 2003-05-16 2010-03-15 Univ Laval CNS-chloridmodulering og anvendelser deraf
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
ES2864206T3 (es) 2003-06-02 2021-10-13 Univ Massachusetts Métodos y composiciones para mejorar la eficacia y la especificidad del ARNi
EP2284268A3 (de) 2003-06-12 2012-05-30 Alnylam Pharmaceuticals Inc. Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
ITRM20030395A1 (it) * 2003-08-12 2005-02-13 Istituto Naz Per Le Malattie Infettive Lazz Terreno di coltura per il mantenimento, la proliferazione e il differenziamento di cellule di mammifero.
CA2540244A1 (en) * 2003-09-30 2005-04-14 Lexicon Genetics Incorporated Methods and compositions for defining gene function
DK1677735T3 (da) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
EP1918000A2 (de) 2003-11-05 2008-05-07 Schering Corporation Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
CA2553745A1 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
EP1735009A4 (de) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc Irna mittel targeting vegf
US20050223202A1 (en) * 2004-03-31 2005-10-06 Intel Corporation Branch prediction in a pipelined processor
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
AU2005326817B2 (en) 2004-05-21 2012-04-19 Benaroya Research Institute Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
EP2289535B8 (de) 2004-12-21 2018-08-08 MUSC Foundation for Research Development Zusammensetzungen und methoden zur wundheilung und geweberegenerierung
DE602005027747D1 (de) 2004-12-22 2011-06-09 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
EP1859277A4 (de) 2005-02-17 2010-03-17 Biogen Idec Inc Behandlung neurologischer störungen
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2402435A3 (de) 2005-10-14 2012-03-28 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
RS54111B1 (en) 2005-11-18 2015-12-31 Glenmark Pharmaceuticals S.A. ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
CN103989710B (zh) * 2005-12-21 2019-11-15 鲁汶大学 分离的肝脏干细胞
JP2009523129A (ja) 2006-01-05 2009-06-18 ユニバーシティ オブ ユタ リサーチ ファウンデーション 神経系を標的する薬理学的物質の性質を改善することに関連する方法および組成物
CA2644952A1 (en) 2006-03-01 2007-09-13 The University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
ES2544861T3 (es) 2006-03-31 2015-09-04 Alnylam Pharmaceuticals Inc. Composiciones y métodos para inhibir la expresión del gen Eg5
US7691824B2 (en) 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
NZ572666A (en) 2006-05-11 2010-11-26 Alnylam Pharmaceuticals Inc Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
WO2007137156A2 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
US7888498B2 (en) 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
JP5496658B2 (ja) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
AU2007297535C1 (en) 2006-09-21 2017-11-23 University Of Florida Research Foundation, Inc. Compositions and methods related to protein displacement therapy for myotonic distrophy
CA3045637A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
EP2101567A4 (de) 2007-01-18 2010-04-21 Univ Utah Res Found Zusammensetzungen und verfahren zur erkennung, behandlung oder prävention von reduktivem stress
EP2111553B1 (de) 2007-01-24 2018-09-19 Carnegie Mellon University Optische biosensoren
WO2008121437A2 (en) 2007-02-08 2008-10-09 The Burnham Institute For Medical Research Trophinin-binding peptides and uses thereof
CN101801185A (zh) 2007-03-22 2010-08-11 耶鲁大学 与控制可变剪接的核糖开关有关的方法和组合物
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
EP2155894A4 (de) 2007-05-09 2010-08-18 Burnham Inst Medical Research Wirtsproteinasen als ziel für eine therapeutische strategie gegen virale und bakterielle krankheitserreger
EP2426219A1 (de) 2007-05-29 2012-03-07 Yale University Riboswitches sowie Verfahren und Zusammensetzungen zur Verwendung von und mit Riboswitches
CN101688206B (zh) 2007-07-05 2013-05-15 诺瓦提斯公司 用于治疗病毒感染的dsRNA
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
EP2617828B1 (de) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
AU2009221775B2 (en) 2008-03-05 2015-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
CA2725208A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US8946291B2 (en) 2008-08-15 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating pigmentary conditions and melanoma
EP3208337A1 (de) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
EP3584320A1 (de) 2008-09-25 2019-12-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
CN106834291B (zh) 2008-10-20 2020-09-29 阿尔尼拉姆医药品有限公司 抑制运甲状腺素蛋白表达的组合物和方法
US20110217725A1 (en) * 2008-10-24 2011-09-08 Kuraray Co., Ltd. Cell culture kit, screening method, and method of manufacturing cell culture kit
KR20110094029A (ko) 2008-11-10 2011-08-19 알렉시온 파마슈티칼스, 인코포레이티드 보체-관련된 장애를 치료하는 방법 및 조성물
WO2010065617A1 (en) 2008-12-02 2010-06-10 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
AU2009324534B2 (en) 2008-12-10 2015-07-30 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
EP2752427A1 (de) 2009-02-24 2014-07-09 Alexion Pharmaceuticals, Inc. Antikörper mit therapeutischen mimetischen TPO-/EPO-Peptiden
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
KR101764437B1 (ko) 2009-03-20 2017-08-02 메소블라스트, 아이엔씨. 재프로그램된 다분화능 세포의 생성 방법
WO2010132665A1 (en) 2009-05-15 2010-11-18 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SG182365A1 (en) 2010-01-12 2012-08-30 Univ Yale Structured rna motifs and compounds and methods for their use
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
WO2011088391A2 (en) 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
JP5860029B2 (ja) 2010-03-29 2016-02-16 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスチレチン（ＴＴＲ）関連眼アミロイドーシスのためのｓｉＲＮＡ療法
ES2623799T3 (es) 2010-04-30 2017-07-12 Alexion Pharmaceuticals, Inc. Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
WO2012021554A1 (en) 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US10004826B2 (en) 2010-10-06 2018-06-26 Massachusetts Institute Of Technology Implantable human liver tissue constructs and uses thereof
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
WO2012082494A2 (en) 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
WO2012082942A2 (en) 2010-12-15 2012-06-21 Neuroadjuvants, Inc. Neuropeptide analogs, compositions, and methods for treating pain
US9958458B2 (en) 2010-12-27 2018-05-01 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
EP2709664A4 (de) 2011-05-20 2015-06-10 Us Government Blockade von tl1a-dr3-interaktionen zur linderung von t-zellen-vermittelten erkrankungen und antikörper dafür
EP2717909B1 (de) 2011-06-04 2017-12-06 Rochester General Hospital Research Institute Zusammensetzungen und verfahren in zusammenhang mit p6 von haemophilus influenzae
EP2723351B1 (de) 2011-06-21 2018-02-14 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
MX344807B (es) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
SG11201404608WA (en) 2012-02-13 2014-09-26 Gamida Cell Ltd Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9856474B2 (en) 2013-01-16 2018-01-02 Iowa State University Research Foundation, Inc. Deep intronic target for splicing correction on spinal muscular atrophy gene
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
JP6431035B2 (ja) 2013-03-13 2018-11-28 ジーンウィーブ バイオサイエンシズ，インコーポレイティド 非複製的形質導入粒子及び形質導入粒子に基づくレポーターシステム
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
EP3521431A1 (de) 2013-09-25 2019-08-07 Cornell University Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
WO2015123561A2 (en) 2014-02-14 2015-08-20 University Of Utah Research Foundation Methods and compositions for inhibiting retinopathy of prematurity
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
AU2015236165A1 (en) 2014-03-25 2016-10-13 University Of Utah Research Foundation Peptide inhibitors of Bcr-Abl oligomerization
HUE052781T2 (hu) 2014-07-24 2021-05-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára
WO2016118832A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
US20180215801A1 (en) 2015-01-29 2018-08-02 Board Of Trustees Of Michigan State University Cryptic polypeptides and uses thereof
LT3265568T (lt) 2015-03-06 2020-08-25 Massachusetts Eye & Ear Infirmary Genų augmentacijos terapijos, skirtos paveldimai tinklainės degeneracijai, sukeltai prpf31 geno mutacijos
EP3735982A1 (de) 2015-03-10 2020-11-11 The University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
WO2016183183A1 (en) 2015-05-11 2016-11-17 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
WO2016183585A1 (en) 2015-05-14 2016-11-17 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
WO2017062757A1 (en) 2015-10-08 2017-04-13 Massachusetts Institute Of Technology In situ expansion of engineered devices for regeneration
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
WO2018191599A1 (en) 2017-04-14 2018-10-18 University Of Massachusetts Brown fat-selective adipokines
EA202090149A1 (ru) 2017-06-28 2020-05-31 Ридженерон Фармасьютикалз, Инк. Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
EP3658184B1 (de) 2017-07-27 2023-09-06 Alexion Pharmaceuticals, Inc. Hochkonzentrierte anti-c5-antikörperformulierungen
CN111670033A (zh) 2017-10-18 2020-09-15 华盛顿大学 作为神经变性疾病或病症的治疗策略的显性阴性sarm1分子
US11008602B2 (en) 2017-12-20 2021-05-18 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
AU2019276372A1 (en) 2018-06-01 2020-12-24 Evotec International Gmbh Combination therapy for treating hepatitis B virus infection
EA202190315A1 (ru) 2018-07-19 2021-04-16 Ридженерон Фармасьютикалз, Инк. Химерные антигенные рецепторы со специфичностью к bcma и их применение
EA202191107A1 (ru) 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
CN113227404A (zh) 2018-12-27 2021-08-06 豪夫迈·罗氏有限公司 用于检测鲍氏不动杆菌的非复制型转导颗粒和基于转导颗粒的报告系统
US11572595B2 (en) 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
CA3147903A1 (en) 2019-07-24 2021-01-28 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
AU2020397416A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis B infection
CN115052625A (zh) 2019-12-03 2022-09-13 埃沃特克国际有限责任公司 干扰素相关抗原结合蛋白及其用途
US20220356537A1 (en) 2019-12-31 2022-11-10 Roche Molecular Systems, Inc. Quantitative pcr screening of inducible prophage from bacterial isolates
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
US20230060095A1 (en) 2020-01-24 2023-02-23 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
MX2022013176A (es) 2020-04-24 2022-11-30 Millennium Pharm Inc Anticuerpos anti cumulo de diferenciacion 19 (cd19) y sus usos.
EP4146697A1 (de) 2020-05-05 2023-03-15 Regeneron Pharmaceuticals, Inc. Auto mit cd28zeta und cd3zeta
EP4188965A1 (de) 2020-07-14 2023-06-07 Massachusetts Institute of Technology Synthetische heparinmimetika und verwendungen davon
KR20230069961A (ko) 2020-09-14 2023-05-19 보르 바이오파마 인크. Cd33에 대한 단일 도메인 항체
JP2024505790A (ja) 2020-12-18 2024-02-08 モメンタ ファーマシューティカルズ インコーポレイテッド インテグリンアルファ１１ベータ１に対する抗体
JP2024502295A (ja) 2020-12-24 2024-01-18 ノボキュア ゲーエムベーハー 遺伝子治療において交流電場を使用するための方法及び組成物
JP2024515066A (ja) 2021-04-09 2024-04-04 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
US20230018888A1 (en) 2021-04-26 2023-01-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
US20230111279A1 (en) 2021-04-26 2023-04-13 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
CA3217914A1 (en) 2021-05-04 2022-11-10 Kevin BRAY Chimeric antigen receptors with mage-a4 specificity and uses thereof
EP4351732A1 (de) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023201238A1 (en) 2022-04-11 2023-10-19 Vor Biopharma Inc. Binding agents and methods of use thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US5580776A (en) * 1988-02-05 1996-12-03 Howard Hughes Medical Institute Modified hepatocytes and uses therefor
WO1989007136A2 (en) * 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy

Also Published As

Publication number Publication date
US5521076A (en) 1996-05-28
DE68927996D1 (de) 1997-05-28
EP0732397A3 (de) 1996-10-23
US6224858B1 (en) 2001-05-01
EP0732397A2 (de) 1996-09-18
DE68927996T2 (de) 1997-12-04
CA1341319C (en) 2001-11-13
US6316255B1 (en) 2001-11-13
EP0400047B1 (de) 1997-04-23
WO1989007136A3 (en) 1989-08-24
EP0400047A1 (de) 1990-12-05
JPH03503718A (ja) 1991-08-22
JP2917998B2 (ja) 1999-07-12
WO1989007136A2 (en) 1989-08-10

Similar Documents

Publication Publication Date Title
ATE152169T1 (de) Modifizierte hepatozyten und deren anwendung
ZA917890B (en) Insect-specific paralytic neurotoxin genes for use in biological insect control:methods and compositions
DE69111550D1 (de) Apparat zur Herstellung von Kohlenstoffasern.
DK219087A (da) Vektorsystem til brug ved transformation af trichoderma, transformerede trichodermastammer og fremgangsmaade til fremstilling af proteiner heri
ATE198621T1 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
NO850040L (no) Baneformede fiberstrukturer og fremgangsmaate for deres fremstilling
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
ATE108828T1 (de) Hybrides rns-virus.
DK448988D0 (da) Praeparat af et alfa-amideringsenzym og fremgangsmaade til fremstilling og anvendelse deraf
DE59206730D1 (de) Virales Agens assoziiert mit der Mystery Swine Disease
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ES2085089T5 (es) Percarbonatos sodicos estabilizados mediante revestimiento.
GEP20043349B (en) Methods of Controlling Cutworm Pests
DK0655454T3 (da) Fremgangsmåde til fremstilling af 2,2-difluorketensilylacetaler og alfa,alfa-difluor-beta-silyloxy-1,3-dioxolan-4-propansyreestere
DE69232945T2 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
NZ209467A (en) Herbicidal composition derived from phomopsis cirsii and septoria cirsii
DE69015962T2 (de) Verbundmaterial, Herstellungsverfahren und Verwendung dieses Materials.
DE69333261D1 (de) KLONIERUNG UND EXPRESSION VON DEM beta APP-C100 REZEPTOR
DK713188A (da) Fremgangsmaade til fremstilling af pregneno-oxazoliner
ATE239074T1 (de) Transduktion von menschlichen hämatopoiestischen stammzellen
FR2665708B1 (fr) Materiau ecran pour serres, l'agriculture et l'horticulture.
JPS566593A (en) Diaphragm
EP0050074A3 (en) Methyl esters of 2,2-dimethyl cyclopropane-1,3-dicarboxylic acid, their preparation and intermediales obtained

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee